Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models

Table 1

Neuroblastoma cell lines used in this study.

Cell line	Site	Stage	Patient age	Phase of therapy	MYCN amp	p53 mutant
CHLA-15	Tumor	4	>1	DX	N	WT
CHLA-20	Tumor	4	1.5	PD-Ind	N	WT
CHLA-90	BM	4	8.5	PD-Auto-BMT	N	Mut
LAN-5	BM	Unknown	0.4	Unknown	A	WT
NUB-7	LN	4s/4	0.7	Unknown	A	WT
SH-SY5Y	BM	4	4	PD-Ind	N	WT
BE(2)C	BM	4	2.2	PD-Ind	A	Mut
SK-N-BE(2)	BM	4	2.2	PD-Ind	A	Mut

BM = bone marrow; B = bone; L = liver; P = pulmonary; LN = lymph node; DX = at diagnosis; PD-Ind = progressive disease on induction chemotherapy; BMT = bone marrow transplantation; PD-Auto-BMT = relapsed after myeloablative chemo-radiotherapy followed by bone marrow transplantation; WT =wild type; Mut = mutant; N = nonamplified; A = amplified.